1. Practices and Tips for Successful Technology Transfer
Dr. Tamar Raz
CEO, Hadasit
Practices and Tips for Successful Technology Transfer
an Academic Hospital Point of View

2. Hadasit Corporate Structure
Hadassah
100%
Established 1912
Established & Incorporated 1986
Hadassah hospitals are public hospitals owned by Hadassah organization which was established 100 years.
Hadasit was established 26 years ago.

3. Hadassah Medical Organization (HMO) - Background
Established in 1912 by “Hadassah” - the Women's Zionist Organization of America:
For more than 100 years, Hadassah and its Hospitals have been leaders in medicine and nursing in Israel:
2 Hospitals (Mt. Scopus & Ein Kerem)
31 Operating theaters
9 Specialty ICUs
1,130 Beds
5,000 Employees
670 Physicians
>1M Outpatients per year

4. Research in Hadassah Hadassah - Center of Excellence >2000
Scientific publications
in the past 5 years
>2000
Hadassah - Center of Excellence
Oncology
Immunology
Neuroscience
Cardiovascular
Infectious Diseases
Metabolic /Liver
Cell Based Therapies
Medical Patent Applications by Israeli Hospitals ( )
…as reflected by the amazing number of grant awards obtained by Hadassah researchers compared to the other hospitals in Israel and publications in peer reviewed scientific articles.
Source: The Israeli Medical Industry, a Patent Analytics Study, Dr. Sharon Bar-Ziv and Inbar Yasur 3

5. Hadasit – Solid Reality and Potential Upside
Technology Transfer Company of Hadassah Medical Hospitals
~ 250
ACTIVE PATENT
FAMILIES
39 %
ALREADY LICENSED

6. Hadasit Selected Partners

7. Licensing Models - Best Practice
Spin-off
High involvement of Tech Transfer and inventor
Funded by business angels and / or incubators
High commitment of founders and Staff
High risk and need for next rounds of funding
Start-up
Funded by venture capital and / or incubators
Seasoned entrepreneurs
Established company
Funded by established company internal budgets
Experienced R&D team
High risk of NIH syndrome
Next round of funding defined
Higher risk of product shelving

8. DOXIL (J&J) for Cancer Treatment
DOXIL - an anti cancer drug, used primarily to treat ovarian and breast cancer
A lipid-based formulation that has a cancer-killing drug inside it.
Prof. Yechezkel Barenholz
Faculty of Medicine, HUJI
Joint Development by Hebrew University and Hadassah Hospital
License to a new start-up company
Technology transferred to Alza cooperation
Alza bough by Johnson & Johnson
Prof. Alberto Gabizon
Hadassah Medical Center
Worldwide sales of DOXIL in 2015 were about US$810 M
Royalties paid to Hebrew University & Hadassah Hospital until patent expirations (Estimated > $ 50M)

9. Travelan® - a Natural Product Specifically Designed to Prevent Travellers’ Diarrhea.
Prof. Yaron Ilan
Immuron’s Chief Medical Officer
Immuron Ltd (ASX Code: IMC) is a publicly listed Australian company delivering Oral Immunotherapy for the treatment and prevention of disease using dairy-derived antibody products for humans. 
Technology was licensed to Immuron by Hadasit in 2009
Travelan & Protectyn sales already producing royalties payments to Hadasit , and are expected to grow in the coming years
Next generation product, based on Hadassah technology is IMM-124E , a natural product for the treatment of Fatty Liver and NASH. Currently in phase II clinical trials.

10. Granagard™ – a Natural Antioxidant for the Prevention and Treatment of Neurodegenerative Conditions.
Granalix BioTechnologies focuses on developing science-based novel formulations of natural antioxidants. GranaGard™, a submicron self-emulsion formulation of pomegranate seed oil (PSO), is a supplement rich in Omega 5 - one of the strongest natural antioxidants. GranaGard™ was shown to prevent neurodegeneration diseases in mouse models, while showing high safety profile after long term administration
First Patent Application
April 2012
New Co Established and Technology Licensed
March 2014
World Wide Sales Initiation
March 2017
Prof. Ruth Gabizon
Hadassah Medical Center

11. Novel Enteral Feeding Device
The novel device eliminates the drawbacks plaguing existing devices and offers a secure, reliable, and discreet enteral feeding solution.
Physicians morning meeting: Another case of accidental percutaneous endoscopic gastrostomy (PEG) dislodgement
The problem was identified by Dr. Ishay Benuri, a young physician that came to Hadasit with suggested solution (drawing on a napkin)
First Patent Application – June 2013
License to an Incubator Start Up Company (Sep 2014)
2017 Status:
Over $1 million raised
A clinical trial is ongoing at Hadassah

12. Identifying Innovation
Passive process
Active process
Scouting
Creating thinking groups
Innovation training
Partnerships

13. BioDesign Innovation
An academic program which creates groups of Medical Students, Engineering Students, Business Students, and Law Students working together toward a single Biotech Product
Original concept - Stanford University
Needs
Analysis
Inception
Design
Prototype
Provisional Patent
Business Plan
Hadassah
Medical Organization
Bioengineering
Hebrew University
Biodesign is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and Hadassah Medical Center. The program takes outstanding medical fellows, bioengineering and business graduate students and tutors them in the science and practice of bringing a medical innovation to the market.
Biodesign  innovation  is  taught by  Hebrew  University  faculty, clinical experts, medical  device  entrepreneurs,  corporate  executives,  intellectual  property  attorneys,  and  venture  capitalists.  As  such,  it  provides  a  unique  opportunity to  gain  real  world  experience  in  an  academic environment growing a new generation of innovators

14. Evaluating Innovation
Identifying unmet need
Map existing solutions – also those under R&D
Evidence in literature – is this important to others?
Joint discussion BD & IP:
IP: Is this new?
BD: Is it important?

15. Business Models How can the technology make money?
What is the product?
How / where are the alternatives being sold?
Disposable / reusable (Razor & blades / Capital)
Current reimbursement status
What is the potential? Market Size?

16. Potential Commercial Partners
Who has an interest? Companies in the field Companies looking to enter the field Entrepreneurs
What are they looking for?
Market leader’s perspective
Upcoming competition perspective
Entrepreneur’s perspective
What POC needs to be achieved?
“Drawing on a napkin”
Initial feasibility – quick and dirty
Proof of concept – pre-clinical
Full R&D – bring a product to the market
Clinical studies $
Possibly independent $ $ $ $ $ $ $ $ $
Requires commercial entity $ $ $ $ $ $ $ $ $ $ $

17. Business Models Doctors have day (and sometimes night) jobs…
Time, finance and R&D expertise will determine how far I can promote the technology independently before…
Establishing a startup
Partnering with an existing company

18. Establishing a Startup – Pros & Cons
Focus on the technology
Flexibility in R&D
Adaptable approach to the market
Maximal motivation to succeed
“Exit” potential
Cons
Raising money
Low chance to succeed
Maximal distance to market
Barriers for entering the market
No financial security – survival mode
“One shot at the target”

19. Partnering with an Existing Company – Pros & Cons
Secured means for development
Shorter time to market
Low barriers for entering the market
Existing know how and capabilities
Cons
Lower motivation
Other agenda
Less flexibility in R&D
Less adaptiveness in approaching the market
No “Exit”…

20. License Agreement License Agreement shall Include:
Granting a royalty-bearing license to practice the licensed technology and/or the results of sponsored research
Funding for ongoing research
Preserving hospital personnel's right to publish
Providing for fair compensation to the hospital if the product is successful in the marketplace
Ensuring that the licensed technologies reach the marketplace in a timely manner for the benefit of the public by the inclusion of development milestones

21. License Considerations
Upfront Payment
License Fees
Milestone Payments
Sublicense Receipts
Royalties from Sales
Sales Milestones
Equity Participation
Exit Fees

22. Thank you. For further information please contact